NASDAQ:GLTO

Galecto Competitors

$6.28
+0.43 (+7.35 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.91
Now: $6.28
$6.54
50-Day Range
$5.85
MA: $8.62
$12.40
52-Week Range
$5.77
Now: $6.28
$17.99
Volume169,167 shs
Average Volume30,944 shs
Market Capitalization$158.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Galecto (NASDAQ:GLTO) Vs. XENE, KDMN, ALBO, KDNY, MGTA, and EOLS

Should you be buying GLTO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Galecto, including Xenon Pharmaceuticals (XENE), Kadmon (KDMN), Albireo Pharma (ALBO), Chinook Therapeutics (KDNY), Magenta Therapeutics (MGTA), and Evolus (EOLS).

Galecto (NASDAQ:GLTO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 8.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galecto and Xenon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GalectoN/AN/AN/AN/AN/A
Xenon Pharmaceuticals$6.83 million92.38$-41,600,000.00($1.54)-11.44

Galecto has higher earnings, but lower revenue than Xenon Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Xenon Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galecto00303.00
Xenon Pharmaceuticals00503.00

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Xenon Pharmaceuticals has a consensus price target of $25.25, suggesting a potential upside of 43.30%. Given Galecto's higher possible upside, research analysts clearly believe Galecto is more favorable than Xenon Pharmaceuticals.

Profitability

This table compares Galecto and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GalectoN/AN/AN/A
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Galecto (NASDAQ:GLTO) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

94.8% of Kadmon shares are owned by institutional investors. 3.0% of Kadmon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galecto and Kadmon's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GalectoN/AN/AN/AN/AN/A
Kadmon$5.09 million123.55$-61,370,000.00($0.74)-4.95

Galecto has higher earnings, but lower revenue than Kadmon.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Kadmon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galecto00303.00
Kadmon00503.00

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Kadmon has a consensus price target of $12.75, suggesting a potential upside of 248.36%. Given Kadmon's higher possible upside, analysts clearly believe Kadmon is more favorable than Galecto.

Profitability

This table compares Galecto and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GalectoN/AN/AN/A
Kadmon-768.36%-85.07%-46.46%

Summary

Kadmon beats Galecto on 5 of the 8 factors compared between the two stocks.

Galecto (NASDAQ:GLTO) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

85.7% of Albireo Pharma shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galecto and Albireo Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GalectoN/AN/AN/AN/AN/A
Albireo Pharma$9.64 million65.19$-62,720,000.00($5.04)-6.52

Galecto has higher earnings, but lower revenue than Albireo Pharma.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Albireo Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galecto00303.00
Albireo Pharma00803.00

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Albireo Pharma has a consensus price target of $72.00, suggesting a potential upside of 118.98%. Given Galecto's higher possible upside, research analysts clearly believe Galecto is more favorable than Albireo Pharma.

Profitability

This table compares Galecto and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GalectoN/AN/AN/A
Albireo Pharma-751.53%-71.22%-42.91%

Galecto (NASDAQ:GLTO) and Chinook Therapeutics (NASDAQ:KDNY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Galecto and Chinook Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galecto00303.00
Chinook Therapeutics00803.00

Galecto currently has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Chinook Therapeutics has a consensus price target of $30.3333, suggesting a potential upside of 104.68%. Given Galecto's higher possible upside, research analysts clearly believe Galecto is more favorable than Chinook Therapeutics.

Profitability

This table compares Galecto and Chinook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GalectoN/AN/AN/A
Chinook Therapeutics-215.80%-112.72%-21.36%

Valuation and Earnings

This table compares Galecto and Chinook Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GalectoN/AN/AN/AN/AN/A
Chinook Therapeutics$17.26 million36.20$-82,370,000.00($5.15)-2.88

Galecto has higher earnings, but lower revenue than Chinook Therapeutics.

Summary

Galecto beats Chinook Therapeutics on 4 of the 6 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

59.3% of Magenta Therapeutics shares are owned by institutional investors. 10.9% of Magenta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Magenta Therapeutics and Galecto, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
Galecto00303.00

Magenta Therapeutics currently has a consensus target price of $17.6667, suggesting a potential upside of 43.40%. Galecto has a consensus target price of $14.00, suggesting a potential upside of 122.93%. Given Galecto's higher possible upside, analysts plainly believe Galecto is more favorable than Magenta Therapeutics.

Profitability

This table compares Magenta Therapeutics and Galecto's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
GalectoN/AN/AN/A

Earnings and Valuation

This table compares Magenta Therapeutics and Galecto's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-5.95
GalectoN/AN/AN/AN/AN/A

Evolus (NASDAQ:EOLS) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

21.7% of Evolus shares are owned by institutional investors. 10.1% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Evolus and Galecto, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14402.33
Galecto00303.00

Evolus currently has a consensus target price of $13.8889, suggesting a potential upside of 2.27%. Galecto has a consensus target price of $14.00, suggesting a potential upside of 122.93%. Given Galecto's stronger consensus rating and higher possible upside, analysts plainly believe Galecto is more favorable than Evolus.

Profitability

This table compares Evolus and Galecto's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
GalectoN/AN/AN/A

Earnings and Valuation

This table compares Evolus and Galecto's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million17.01$-90,030,000.00($3.19)-4.26
GalectoN/AN/AN/AN/AN/A

Galecto has lower revenue, but higher earnings than Evolus.

Summary

Galecto beats Evolus on 5 of the 9 factors compared between the two stocks.


Galecto Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62+1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66+5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88+2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82+3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32+9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58+2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23+2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87+6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04+4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52+3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07+4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44+2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26+1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20+5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56+0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10+0.6%$544.91 million$26.74 million17.75
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66+5.1%$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04+0.2%$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32+0.0%$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87+4.3%$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28+0.2%$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04+5.1%$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44+10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78+0.0%$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00+21.6%$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97+0.9%$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00+0.3%$502.28 million$58.12 million-16.28
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.72+1.2%$500.13 million$57.49 million-6.49
XBiotech logo
XBIT
XBiotech
1.0$16.95+0.4%$499.33 millionN/A1.17
AC Immune logo
ACIU
AC Immune
1.3$6.87+0.6%$494.21 million$111.75 million-7.63
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.53+6.6%$494.19 millionN/A-2.59Gap Down
Altimmune logo
ALT
Altimmune
1.9$12.90+1.7%$479.24 million$5.80 million-6.48
Akouos logo
AKUS
Akouos
1.6$13.87+1.4%$477.16 millionN/A0.00News Coverage
Verastem logo
VSTM
Verastem
1.1$2.76+1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07+3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48+2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.18+2.4%$469.72 million$6.68 million-5.04
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.06+3.3%$469.72 million$335 million-1.03Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.63+3.4%$466.82 million$56.50 million0.00Analyst Upgrade
Gap Up
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.57+4.1%$465.95 million$6.07 million-3.62Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23+0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
BCEL
Atreca
1.7$12.29+3.4%$452.65 millionN/A-4.36Gap Down
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.29+3.1%$452.48 millionN/A0.00Gap Up
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.33+2.3%$449.56 million$102.31 million6.46
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.02+1.4%$446.29 millionN/A0.00News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8N/AN/A$439.81 millionN/A-3.55
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.92+3.9%$438.87 millionN/A-12.08News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$38.99+0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
Sesen Bio logo
SESN
Sesen Bio
1.2$2.52+3.2%$426.85 millionN/A-5.73Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.